Since the aberrant activity of the PI3K/AKT/mTOR pathway was commonly observed in cancers, and mTOR inhibitors were used in clinical trials, our current comprehensive results offer an opportunity to discern the molecular mechanism involved in inhibition of the signaling pathway in MPN. This evidence concerns the gene AKT1 and myeloproliferative neoplasm.